FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BLICKENSTAFF KIM D					2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [TNDM]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
DEICKENSTAFT KIM D													X Director			10% C	wner		
(Last)	Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 05/23/2024								Officer (give title below)			Other below)	(specify		
12400 HIGH BLUFF DRIVE				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)													2	Y Form fi	led by On	e Repo	rting Perso	on	
SAN DII	EGO C	A	92130										Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)		Rı	Rule 10b5-1(c) Transaction Indication													
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is int the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										at is intende	d to satisfy								
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1)		(A) or 3, 4 and 5)	Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership					
							Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)			
Common Stock 05/24/2				1/2024	2024		M		4,434	A	\$51.73	17,8	17,848		D				
Common Stock												205,190				See Footnote ⁽¹⁾			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	itle of 2. 3. Transaction Jak. Deemed Execution Date Execution Date, urity or Exercise (Month/Day/Year) if any		4. Transa Code (I 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)				
				Ī									Amount		(Instr. 4)	uon(s)			
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Number of Shares						
Restricted Stock Unit ⁽²⁾	(3)	05/24/2024			М	М		4,434	(4)		(4)	Common Stock	4,434	\$0	0		D		
Restricted Stock Unit ⁽⁵⁾	(3)	05/23/2024			A		4,387		(4)		(4)	Common Stock	4,387	\$0	4,38	37	D		

Explanation of Responses:

- 1. The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010.
- 2. Awarded on May 24, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan).
- 3. Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023
- 4. RSU will vest on the one-year anniversary of the grant date, subject to the terms of the 2023 Plan.
- 5. Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan).

Remarks:

/s/ Rachel Malina, Attorney-in-Fact for Kim D. Blickenstaff ** Signature of Reporting Person

05/24/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.